2022-03-06T00:00:00.000+00:00
Ongoing
SAMETA
SAMETA
Genitourinary cancer
A Phase III, Open Label, Randomised, 3-Arm, Multi-Centre Study of Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic Papillary Renal Cell Carcinoma
A Phase III, Open Label, Randomised, 3-Arm, Multi-Centre Study of Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic Papillary Renal Cell Carcinoma
Trial overview
Clinical Area
Medical Oncology
Disease / Condition
Renal
Study Phase
III
Trial Identifiers
Registration number: NCT05043090